

# Cancer Pain - Pipeline Review, H1 2020

<https://marketpublishers.com/r/CAE3BB8B265EN.html>

Date: May 2020

Pages: 155

Price: US\$ 2,000.00 (Single User License)

ID: CAE3BB8B265EN

## Abstracts

Cancer Pain - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cancer Pain – Pipeline Review, H1 2020, provides an overview of the Cancer Pain (Central Nervous System) pipeline landscape.

Cancer pain can be defined as a complex sensation that reflects both damage to the body and the body's response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or from skin, nerve and other changes caused by either the body's immune response or hormones released by the tumor. Cancer pain can be treated by analgesic drug therapy, non-opioid analgesics, opioid analgesics, adjuvant drugs, psychotherapy, anesthetic and neurosurgical pain management.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cancer Pain – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Cancer Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cancer Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cancer Pain and features dormant and

discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 6, 7, 7, 1, 16, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.

Cancer Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Pain (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Cancer Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Cancer Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Cancer Pain (Central Nervous System)

therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Pain (Central Nervous System)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Cancer Pain (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Cancer Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



## Contents

Introduction

Cancer Pain - Overview

Cancer Pain - Therapeutics Development

Cancer Pain - Therapeutics Assessment

Cancer Pain - Companies Involved in Therapeutics Development

Cancer Pain - Drug Profiles

Cancer Pain - Dormant Projects

Cancer Pain - Discontinued Products

Cancer Pain - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Cancer Pain, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Cancer Pain - Pipeline by Alexza Pharmaceuticals Inc, H1 2020

Cancer Pain - Pipeline by AngioChem Inc, H1 2020

Cancer Pain - Pipeline by Aphios Corp, H1 2020

Cancer Pain - Pipeline by Aquilus Pharmaceuticals Inc, H1 2020

Cancer Pain - Pipeline by AstraZeneca Plc, H1 2020

Cancer Pain - Pipeline by Beckley Canopy Therapeutics Ltd, H1 2020

Cancer Pain - Dormant Projects, H1 2020

Cancer Pain - Dormant Projects, H1 2020 (Contd..1), H1 2020

Cancer Pain - Dormant Projects, H1 2020 (Contd..2), H1 2020

Cancer Pain - Dormant Projects, H1 2020 (Contd..3), H1 2020

Cancer Pain - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Cancer Pain, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Molecule Types, H1 2020  
Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

Alexza Pharmaceuticals Inc  
AngioChem Inc  
Aphios Corp  
Aquilus Pharmaceuticals Inc  
AstraZeneca Plc  
Beckley Canopy Therapeutics Ltd  
Cassava Sciences Inc  
Concentric Analgesics Inc  
Daewoong Pharmaceutical Co Ltd  
Dompe Farmaceutici SpA  
Fujimoto Pharmaceutical Corp  
Hisamitsu Pharmaceutical Co Inc  
Intec Pharma Ltd  
IntelGenx Corp  
iX Biopharma Ltd  
Klaria Pharma Holding AB  
Komipharm International Co Ltd  
Luye Pharma Group Co Ltd  
Medlab Clinical Ltd  
Mundipharma International Ltd  
Nanomerics Ltd  
Neurocentrx Pharma Ltd

Nippon Kayaku Co Ltd  
Nippon Zoki Pharmaceutical Co Ltd  
Oblique Therapeutics AB  
Orion Corp  
Pfizer Inc  
Pharmaleads SA  
ProNeurogen Inc  
Recordati SpA  
Ribomic Inc  
Sedor Pharmaceuticals LLC  
Sorrento Therapeutics Inc  
Tetra Bio-Pharma Inc  
Virobay Inc  
WEX Pharmaceuticals Inc  
Winston Pharmaceuticals Inc  
Yongzhan International Pharmaceutical Co Ltd



## I would like to order

Product name: Cancer Pain - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/CAE3BB8B265EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CAE3BB8B265EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970